The immune system is comprised of many cellular subsets. Flow cytometry has become a very powerful tool to precisely quantify and characterize the phenotype of innate and adaptive cellular subsets. Flow cytometry distinguishes a subpopulation from a heterogeneous mixture and evaluates the impact of an agent (antigen, drug) on a particular immune subset.
ImmuneCarta offers state-of-the-art flow cytometry based assays to characterize immune cell subpopulations and the relationship between phenotypic and functional attributes.
Benefits and Applications
- Use of qualified backbone panels for identifying major cell lineages of the innate and adaptive arms of the immune system in different specimen types: Whole blood, PBMC (peripheral blood mononuclear cells), Tissue.
- T cell lineage and memory/activation markers (CD3+, CD4+/-, CD8+/-, HLA-DR+/-, CD38+/-)
- Naïve (CD45RA+, CD27+, CCR7+)
- Central memory (CD45RA-, CD27+, CCR7+)
- Transitional memory (CD45RA-, CD27+, CCR7-)
- Effector memory (CD45RA-, CD27-, CCR7-)
- Late-differentiated effectors (CD45RA+, CD27-, CCR7-)
- B cell lineage and memory/activation markers (CD3-, CD19+, CD27+/-, IgD+/-, CD24+/-, CD38+)
- Regulatory T cells and memory activation markers (CD3+, CD4+, CCR4+, CD25+, CD127+, CD45RO+/-, HLA-DR)
- T helper subsets and memory/activation markers (CD3+, CD4+, CD45RA, CD38, HLA-DR)
- Th1 (CXCR3+, CCR6-)
- Th2 (CXCR3-, CCR6-)
- Th17 (CXCR3-, CCR6+)
- NK cells (CD3-, CD19-, CD14-, CD20-, CD16+, CD56+/-)
- Monocytes (CD3-, CD19-, CD14+, CD16+/-)
- Dendritic cells (DCs) (CD3-, CD19-, CD14-, CD20-, HLA-DR+)
- Myeloid Dendritic cells (CD11c+)
- Plasmacytoid DCs (CD123+)
- Optional customization for multiplexing biomarkers of choice (see below)
- Detection of Antigen-Specific Responses using HLA-restricted multimers
- Involved in the MHC multimer proficiency testing program
ImmuneCarta offers optional customization for multiplexing biomarkers of choice identifying major cell lineages of the innate and adaptive arms of the immune system.